{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:27:13Z","timestamp":1786368433068,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T00:00:00Z","timestamp":1556841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00198-019-04999-4","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T12:05:00Z","timestamp":1556885100000},"page":"1607-1616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia"],"prefix":"10.1007","volume":"30","author":[{"given":"H.","family":"Chandler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Hattersley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Bouxsein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Lanske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,3]]},"reference":[{"issue":"1","key":"4999_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000014","volume":"1","author":"K Briot","year":"2015","unstructured":"Briot K, Roux C (2015) Glucocorticoid-induced osteoporosis. RMD Open 1(1):e000014","journal-title":"RMD Open"},{"issue":"10","key":"4999_CR2","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","volume":"18","author":"E Canalis","year":"2007","unstructured":"Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18(10):1319\u20131328","journal-title":"Osteoporos Int"},{"issue":"4","key":"4999_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00198-006-0278-8","volume":"18","author":"D Chappard","year":"2007","unstructured":"Chappard D, Josselin N, Rouge-Maillart C, Legrand E, Basle MF, Audran M (2007) Bone microarchitecture in males with corticosteroid-induced osteoporosis. Osteoporos Int 18(4):487\u2013494","journal-title":"Osteoporos Int"},{"issue":"3","key":"4999_CR4","doi-asserted-by":"publisher","first-page":"E587","DOI":"10.1152\/ajpendo.00219.2016","volume":"311","author":"M Piemontese","year":"2016","unstructured":"Piemontese M, Xiong J, Fujiwara Y, Thostenson JD, O'Brien CA (2016) Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice. Am J Physiol Endocrinol Metab 311(3):E587\u2013E593","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"4999_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00223-004-0205-y","volume":"77","author":"S Vedi","year":"2005","unstructured":"Vedi S, Elkin SL, Compston JE (2005) A histomorphometric study of cortical bone of the iliac crest in patients treated with glucocorticoids. Calcif Tissue Int 77(2):79\u201383","journal-title":"Calcif Tissue Int"},{"issue":"9","key":"4999_CR6","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1172\/JCI26239","volume":"115","author":"TJ Martin","year":"2005","unstructured":"Martin TJ (2005) Osteoblast-derived PTHrP is a physiological regulator of bone formation. J Clin Invest 115(9):2322\u20132324","journal-title":"J Clin Invest"},{"issue":"9","key":"4999_CR7","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1172\/JCI24918","volume":"115","author":"D Miao","year":"2005","unstructured":"Miao D, He B, Jiang Y, Kobayashi T, Soroc\u00e9anu MA, Zhao J, Su H, Tong X, Amizuka N, Gupta A, Genant HK, Kronenberg HM, Goltzman D, Karaplis AC (2005) Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest 115(9):2402\u20132411","journal-title":"J Clin Invest"},{"issue":"1","key":"4999_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jbmr.5650100106","volume":"10","author":"CA Walsh","year":"1995","unstructured":"Walsh CA, Birch MA, Fraser WD, Lawton R, Dorgan J, Walsh S, Sansom D, Beresford JN, Gallagher JA (1995) Expression and secretion of parathyroid hormone-related protein by human bone-derived cells in vitro: effects of glucocorticoids. J Bone Miner Res 10(1):17\u201325","journal-title":"J Bone Miner Res"},{"issue":"2","key":"4999_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.steroids.2008.12.002","volume":"74","author":"M Ahlstrom","year":"2009","unstructured":"Ahlstrom M, Pekkinen M, Lamberg-Allardt C (2009) Dexamethasone downregulates the expression of parathyroid hormone-related protein (PTHrP) in mesenchymal stem cells. Steroids 74(2):277\u2013282","journal-title":"Steroids"},{"issue":"4","key":"4999_CR10","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1089\/ten.tea.2009.0355","volume":"16","author":"LF de Castro","year":"2010","unstructured":"de Castro LF, Lozano D, Dapia S, Portal-Nunez S, Caeiro JR, Gomez-Barrena E, Esbrit P (2010) Role of the N- and C-terminal fragments of parathyroid-hormone-related protein as putative therapies to improve bone regeneration under high glucocorticoid treatment. Tissue Eng Part A 16(4):1157\u20131168","journal-title":"Tissue Eng Part A"},{"issue":"11","key":"4999_CR11","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1002\/art.24879","volume":"60","author":"KG Saag","year":"2009","unstructured":"Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60(11):3346\u20133355","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4999_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S8756-3282(00)00251-9","volume":"26","author":"MP Bostrom","year":"2000","unstructured":"Bostrom MP, Gamradt SC, Asnis P, Vickery BH, Hill E, Avnur Z, Waters RV (2000) Parathyroid hormone-related protein analog RS-66271 is an effective therapy for impaired bone healing in rabbits on corticosteroid therapy. Bone 26(5):437\u2013442","journal-title":"Bone"},{"issue":"7","key":"4999_CR13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CAF, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, for the ACTIVE Study Investigators (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316(7):722\u2013733","journal-title":"JAMA"},{"issue":"2","key":"4999_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","volume":"92","author":"F Cosman","year":"2017","unstructured":"Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D (2017) Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis:Results of the ACTIVExtend trial. Mayo Clin Proc 92(2):200\u2013210","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"4999_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00223-016-0171-1","volume":"99","author":"H Bahar","year":"2016","unstructured":"Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G (2016) Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats. Calcif Tissue Int 99(5):489\u2013499","journal-title":"Calcif Tissue Int"},{"key":"4999_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.bone.2016.11.027","volume":"95","author":"A Varela","year":"2017","unstructured":"Varela A, Chouinard L, Lesage E, Guldberg R, Smith SY, Kostenuik PJ, Hattersley G (2017) One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats. Bone 95:143\u2013150","journal-title":"Bone"},{"issue":"1","key":"4999_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jbmr.3003","volume":"32","author":"A Varela","year":"2017","unstructured":"Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G (2017) One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption. J Bone Miner Res 32(1):24\u201333","journal-title":"J Bone Miner Res"},{"issue":"3","key":"4999_CR18","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00198-017-4323-6","volume":"29","author":"N Doyle","year":"2018","unstructured":"Doyle N, Varela A, Haile S, Guldberg R, Kostenuik PJ, Ominsky MS, Smith SY, Hattersley G (2018) Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Osteoporos Int 29(3):685\u2013697","journal-title":"Osteoporos Int"},{"key":"4999_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.bone.2018.10.012","volume":"120","author":"H Chandler","year":"2019","unstructured":"Chandler H, Lanske B, Varela A, Guillot M, Boyer M, Brown J, Pierce A, Ominsky M, Mitlak B, Baron R, Kostenuik P, Hattersley G (2019) Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption. Bone 120:148\u2013155","journal-title":"Bone"},{"issue":"7","key":"4999_CR20","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/jbmr.141","volume":"25","author":"ML Bouxsein","year":"2010","unstructured":"Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25(7):1468\u20131486","journal-title":"J Bone Miner Res"},{"issue":"3","key":"4999_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1439-0264.2011.01119.x","volume":"41","author":"A Cacchioli","year":"2012","unstructured":"Cacchioli A, Ravanetti F, Soliani L, Borghetti P (2012) Preliminary study on the mineral apposition rate in distal femoral epiphysis of New Zealand white rabbit at skeletal maturity. Anat Histol Embryol 41(3):163\u2013169","journal-title":"Anat Histol Embryol"},{"issue":"11","key":"4999_CR22","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1002\/art.23988","volume":"58","author":"T Mawatari","year":"2008","unstructured":"Mawatari T, Miura H, Hamai S, Shuto T, Nakashima Y, Okazaki K, Kinukawa N, Sakai S, Hoffmann PF, Iwamoto Y, Keaveny TM (2008) Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial. Arthritis Rheum 58(11):3340\u20133349","journal-title":"Arthritis Rheum"},{"issue":"1","key":"4999_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00774-007-0797-1","volume":"26","author":"S Castaneda","year":"2008","unstructured":"Castaneda S, Calvo E, Largo R, Gonzalez-Gonzalez R, de la Piedra C, Diaz-Curiel M, Herrero-Beaumont G (2008) Characterization of a new experimental model of osteoporosis in rabbits. J Bone Miner Metab 26(1):53\u201359","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"4999_CR24","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1210\/endo.142.3.8048","volume":"142","author":"AW Eberhardt","year":"2001","unstructured":"Eberhardt AW, Yeager-Jones A, Blair HC (2001) Regional trabecular bone matrix degeneration and osteocyte death in femora of glucocorticoid- treated rabbits. Endocrinology 142(3):1333\u20131340","journal-title":"Endocrinology"},{"issue":"3","key":"4999_CR25","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3109\/17453674.2010.483986","volume":"81","author":"L Baofeng","year":"2010","unstructured":"Baofeng L, Zhi Y, Bei C, Guolin M, Qingshui Y, Jian L (2010) Characterization of a rabbit osteoporosis model induced by ovariectomy and glucocorticoid. Acta Orthop 81(3):396\u2013401","journal-title":"Acta Orthop"},{"key":"4999_CR26","unstructured":"FDA (2016) Osteoporosis: nonclinical evaluation of drugs intended for treatment. Guidance for industry. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM506366.pdf ("},{"issue":"9","key":"4999_CR27","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1600-0501.2012.02495.x","volume":"24","author":"MI Almagro","year":"2013","unstructured":"Almagro MI, Roman-Blas JA, Bellido M, Castaneda S, Cortez R, Herrero-Beaumont G (2013) PTH [1-34] enhances bone response around titanium implants in a rabbit model of osteoporosis. Clin Oral Implants Res 24(9):1027\u20131034","journal-title":"Clin Oral Implants Res"},{"issue":"6","key":"4999_CR28","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s002230010091","volume":"66","author":"T Hirano","year":"2000","unstructured":"Hirano T, Burr DB, Cain RL, Hock JM (2000) Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1-34). Calcif Tissue Int 66(6):456\u2013460","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"4999_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175329","volume":"12","author":"H Yamane","year":"2017","unstructured":"Yamane H, Takakura A, Shimadzu Y, Kodama T, Lee JW, Isogai Y, Ishizuya T, Takao-Kawabata R, Iimura T (2017) Acute development of cortical porosity and endosteal naive bone formation from the daily but not weekly short-term administration of PTH in rabbit. PLoS One 12(4):e0175329","journal-title":"PLoS One"},{"issue":"1","key":"4999_CR30","first-page":"76","volume":"61","author":"CM Bagi","year":"2011","unstructured":"Bagi CM, Berryman E, Moalli MR (2011) Comparative bone anatomy of commonly used laboratory animals: implications for drug discovery. Comp Med 61(1):76\u201385","journal-title":"Comp Med"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-04999-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-019-04999-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-04999-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T16:08:42Z","timestamp":1721232522000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-019-04999-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,3]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["4999"],"URL":"https:\/\/doi.org\/10.1007\/s00198-019-04999-4","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,3]]},"assertion":[{"value":"4 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Funding for this work was provided by Radius Health. HKC, GH, and BL are current or former employees of Radius Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}